×
Choose Speciality

EXPLORE!

LOGIN

By signing up or signing in to eMediNexus, you consent to eMediNexus collecting and using your personal data in accordance with our Privacy Policy. I consent to receive medical updates and communications from eMediNexus, it's parent company IJCP and its industry partners.

Cabozantinib as first-line therapy in patients with metastatic collecting duct renal cell carcinoma

  794 Views

eMediNexus    28 June 2022

Cabozantinib is considered to be the first-line therapeutic choice for patients with metastatic collecting duct carcinoma.
  • Metastatic collecting duct carcinoma is a rare type of non-clear cell renal cell carcinoma with a poor prognosis and no standard treatment guidelines.
  • Studies have provided evidence about the benefit of cabozantinib in ncRCC.
  • BONSAI trial is a prospective study that showed that cabozantinib has efficacy in untreated patients with mCDC. The patients in the study received 60 mg orally once daily. 

Reference: Procopio G, Sepe P, Claps M, et al. Cabozantinib as first-line treatment in patients with metastatic collecting duct renal cell carcinoma. JAMA Oncol. 2022; 8: 910-913. 

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.